Alternative molecular formats and therapeutic applications for bispecific antibodies

Molecular Immunology

Volumn 67, Issue 2, 2015, Pages 95-106

  Spiess, Christoph ^a   Zhai, Qianting ^a   Carter, Paul J ^a  

^a GENENTECH INC   (United States)

Author keywords

Antibody engineering; Antibody therapeutics; Bispecific antibodies

Indexed keywords

ANTIBODY CONJUGATE; BLINATUMOMAB; CATUMAXOMAB; CELL SURFACE RECEPTOR; IMMUNOGLOBULIN G; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CD19 ANTIGEN; CD3 ANTIGEN; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; TUMOR ANTIGEN;

ANTIBODY COMBINING SITE; CELL KILLING; DRUG APPROVAL; DRUG BINDING SITE; DRUG DESIGN; DRUG HALF LIFE; DRUG MECHANISM; EFFECTOR CELL; HEAVY CHAIN; HUMAN; INVESTIGATIVE PROCEDURES; LIGHT CHAIN; MOLECULAR WEIGHT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR CELL; BIOLOGICAL MODEL; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; NEOPLASMS; PROCEDURES;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD19; ANTIGENS, CD3; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL ADHESION MOLECULES; HUMANS; IMMUNOTHERAPY; MODELS, IMMUNOLOGICAL; NEOPLASMS;

EID: 84926348347     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.01.003     Document Type: Review

References (127)

1. Albrecht H., Denardo G.L., Denardo S.J. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility. J. Immunol. Methods 2006, 310:100-116.
2. Alt M., Müller R., Kontermann R.E. Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Lett. 1999, 454:90-94.
3. Arndt M.A., Krauss J., Kipriyanov S.M., Pfreundschuh M., Little M. A bispecific diabody that mediates natural killer cell cytotoxicity against xenotransplantated human Hodgkin's tumors. Blood 1999, 94:2562-2568.
4. Atwell S., Ridgway J.B., Wells J.A., Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J. Mol. Biol. 1997, 270:26-35.
5. Bargou R., Leo E., Zugmaier G., Klinger M., Goebeler M., Knop S., Noppeney R., Viardot A., Hess G., Schuler M., Einsele H., Brandl C., Wolf A., Kirchinger P., Klappers P., Schmidt M., Riethmüller G., Reinhardt C., Baeuerle P.A., Kufer P. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008, 321:974-977.
6. Beckmann, R., 2012. Dual targeting. WO2012163520 A1, Dutalys.
7. Bhatnagar P.K., Das D., Suresh M.R. Sequential affinity purification of peroxidase tagged bispecific anti-SARS-CoV antibodies on phenylboronic acid agarose. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2008, 863:235-241.
8. Bird R.E., Hardman K.D., Jacobson J.W., Johnson S., Kaufman B.M., Lee S.M., Lee T., Pope S.H., Riordan G.S., Whitlow M. Single-chain antigen-binding proteins. Science 1988, 242:423-426.
9. Boersma Y.L., Chao G., Steiner D., Wittrup K.D., Plückthun A. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J. Biol. Chem. 2011, 286:41273-41285.
10. Bossi G., Buisson S., Oates J., Jakobsen B.K., Hassan N.J. ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells. Cancer Immunol. Immunother. 2014, 63:437-448.
11. Bostrom J., Yu S.F., Kan D., Appleton B.A., Lee C.V., Billeci K., Man W., Peale F., Ross S., Wiesmann C., Fuh G. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009, 323:1610-1614.
12. Bregenholt S., Jensen A., Lantto J., Hyldig S., Haurum J.S. Recombinant human polyclonal antibodies: a new class of therapeutic antibodies against viral infections. Curr. Pharm. Des. 2006, 12:2007-2015.
13. Brennan M., Davison P.F., Paulus H. Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 1985, 229:81-83.
14. Byrne H., Conroy P.J., Whisstock J.C., O'Kennedy R.J. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol. 2013, 31:621-632.
15. Chan A.C., Carter P.J. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 2010, 10:301-316.
16. Chang C.H., Rossi E.A., Goldenberg D.M. The dock and lock method: a novel platform technology for building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin. Cancer Res. 2007, 13:5586s-5591s.
17. Chelius D., Ruf P., Gruber P., Ploscher M., Liedtke R., Gansberger E., Hess J., Wasiliu M., Lindhofer H. Structural and functional characterization of the trifunctional antibody catumaxomab. mAbs 2010, 2:309-319.
18. Chon J.H., Zarbis-Papastoitsis G. Advances in the production and downstream processing of antibodies. N. Biotechnol. 2011, 28:458-463.
19. Cochlovius B., Kipriyanov S.M., Stassar M.J., Schuhmacher J., Benner A., Moldenhauer G., Little M. Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3×CD19 tandem diabody, and CD28 costimulation. Cancer Res. 2000, 60:4336-4341.
20. Coppieters K., Dreier T., Silence K., de Haard H., Lauwereys M., Casteels P., Beirnaert E., Jonckheere H., Van de Wiele C., Staelens L., Hostens J., Revets H., Remaut E., Elewaut D., Rottiers P. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum. 2006, 54:1856-1866.
21. Correia I., Sung J., Burton R., Jakob C.G., Carragher B., Ghayur T., Radziejewski C. The structure of dual-variable-domain immunoglobulin molecules alone and bound to antigen. mAbs 2013, 5:364-372.
22. Couch J.A., Yu Y.J., Zhang Y., Tarrant J.M., Fuji R.N., Meilandt W.J., Solanoy H., Tong R.K., Hoyte K., Luk W., Lu Y., Gadkar K., Prabhu S., Ordonia B.A., Nguyen Q., Lin Y., Lin Z., Balazs M., Scearce-Levie K., Ernst J.A., Dennis M.S., Watts R.J. Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci. Transl. Med. 2013, 5. 183ra57, 1-12.
23. Croasdale R., Wartha K., Schanzer J.M., Kuenkele K.P., Ries C., Mayer K., Gassner C., Wagner M., Dimoudis N., Herter S., Jaeger C., Ferrara C., Hoffmann E., Kling L., Lau W., Staack R.F., Heinrich J., Scheuer W., Stracke J., Gerdes C., Brinkmann U., Umana P., Klein C. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. Arch. Biochem. Biophys. 2012, 526:206-218.
24. Das R., Baker D. Macromolecular modeling with rosetta. Annu. Rev. Biochem. 2008, 77:363-382.
25. Davies J., Riechmann L. Antibody VH domains as small recognition units. Biotechnology 1995, 13:475-479.
26. Davis J.H., Aperlo C., Li Y., Kurosawa E., Lan Y., Lo K.M., Huston J.S. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng. Des. Sel. 2010, 23:195-202.
27. Davis, S.J., Smith, E., Macdonald, D., Olson, K.L., 2013. Readily isolated bispecific antibodies with native immunoglobulin format. US Patent 8,586,713. Regeneron Pharmaceuticals, Inc.
28. De Bernardis F., Liu H., O'Mahony R., La Valle R., Bartollino S., Sandini S., Grant S., Brewis N., Tomlinson I., Basset R.C., Holton J., Roitt I.M., Cassone A. Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J. Infect. Dis. 2007, 195:149-157.
29. Demarest S.J., Glaser S.M. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr. Opin. Drug Discov. Devel. 2008, 11:675-687.
30. Desmyter A., Transue T.R., Ghahroudi M.A., Thi M.H., Poortmans F., Hamers R., Muyldermans S., Wyns L. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat. Struct. Biol. 1996, 3:803-811.
31. Dhimolea E., Reichert J.M. World bispecific antibody summit, September 27-28, 2011, Boston, MA. mAbs 2012, 4:4-13.
32. Dimasi N., Gao C., Fleming R., Woods R.M., Yao X.T., Shirinian L., Kiener P.A., Wu H. The design and characterization of oligospecific antibodies for simultaneous targeting of multiple disease mediators. J. Mol. Biol. 2009, 393:672-692.
33. Doppalapudi V.R., Huang J., Liu D., Jin P., Liu B., Li L., Desharnais J., Hagen C., Levin N.J., Shields M.J., Parish M., Murphy R.E., Del Rosario J., Oates B.D., Lai J.Y., Matin M.J., Ainekulu Z., Bhat A., Bradshaw C.W., Woodnutt G., Lerner R.A., Lappe R.W. Chemical generation of bispecific antibodies. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:22611-22616.
34. Doppalapudi V.R., Tryder N., Li L., Aja T., Griffith D., Liao F.F., Roxas G., Ramprasad M.P., Bradshaw C., Barbas C.F. Chemically programmed antibodies: endothelin receptor targeting CovX-Bodies. Bioorg. Med. Chem. Lett. 2007, 17:501-506.
35. Ecker D.M., Jones S.D., Levine H.L. The therapeutic monoclonal antibody market. mAbs 2014, (advanced online publication).
36. Eggel A., Baumann M.J., Amstutz P., Stadler B.M., Vogel M. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage. J. Mol. Biol. 2009, 393:598-607.
37. Els Conrath K., Lauwereys M., Wyns L., Muyldermans S. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J. Biol. Chem. 2001, 276:7346-7350.
38. Emanuel S.L., Engle L.J., Chao G., Zhu R.R., Cao C., Lin Z., Yamniuk A.P., Hosbach J., Brown J., Fitzpatrick E., Gokemeijer J., Morin P., Morse B.A., Carvajal I.M., Fabrizio D., Wright M.C., Das Gupta R., Gosselin M., Cataldo D., Ryseck R.P., Doyle M.L., Wong T.W., Camphausen R.T., Cload S.T., Marsh H.N., Gottardis M.M., Furfine E.S. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. mAbs 2011, 3:38-48.
39. Farrington G.K., Caram-Salas N., Haqqani A.S., Brunette E., Eldredge J., Pepinsky B., Antognetti G., Baumann E., Ding W., Garber E., Jiang S., Delaney C., Boileau E., Sisk W.P., Stanimirovic D.B. A novel platform for engineering blood-brain barrier-crossing bispecific biologics. FASEB J. 2014, 28:4764-4778.
40. Fenn S., Schiller C.B., Griese J.J., Duerr H., Imhof-Jung S., Gassner C., Moelleken J., Regula J.T., Schaefer W., Thomas M., Klein C., Hopfner K.P., Kettenberger H. Crystal structure of an anti-Ang2 CrossFab demonstrates complete structural and functional integrity of the variable domain. PLoS ONE 2013, 8:e61953.
41. Frandsen T.P., Naested H., Rasmussen S.K., Hauptig P., Wiberg F.C., Rasmussen L.K., Jensen A.M., Persson P., Wiken M., Engstrom A., Jiang Y., Thorpe S.J., Forberg C., Tolstrup A.B. Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use. Biotechnol. Bioeng. 2011, 108:2171-2181.
42. Frankel S.R., Baeuerle P.A. Targeting T cells to tumor cells using bispecific antibodies. Curr. Opin. Chem. Biol. 2013, 17:385-392.
43. Friedman M., Lindstrom S., Ekerljung L., Andersson-Svahn H., Carlsson J., Brismar H., Gedda L., Frejd F.Y., Stahl S. Engineering and characterization of a bispecific HER2×EGFR-binding affibody molecule. Biotechnol. Appl. Biochem. 2009, 54:121-131.
44. Glennie M.J., McBride H.M., Worth A.T., Stevenson G.T. Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments. J. Immunol. 1987, 139:2367-2375.
45. Gunasekaran K., Pentony M., Shen M., Garrett L., Forte C., Woodward A., Ng S.B., Born T., Retter M., Manchulenko K., Sweet H., Foltz I.N., Wittekind M., Yan W. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J. Biol. Chem. 2010, 285:19637-19646.
46. Heiss M.M., Murawa P., Koralewski P., Kutarska E., Kolesnik O.O., Ivanchenko V.V., Dudnichenko A.S., Aleknaviciene B., Razbadauskas A., Gore M., Ganea-Motan E., Ciuleanu T., Wimberger P., Schmittel A., Schmalfeldt B., Burges A., Bokemeyer C., Lindhofer H., Lahr A., Parsons S.L. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int. J. Cancer 2010, 127:2209-2221.
47. Holliger P., Prospero T., Winter G. "Diabodies": small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:6444-6448.
48. Holliger P., Wing M., Pound J.D., Bohlen H., Winter G. Retargeting serum immunoglobulin with bispecific diabodies. Nat. Biotechnol. 1997, 15:632-636.
49. Hu S., Fu W., Xu W., Yang Y., Cruz M., Berezov S., Jorissen D., Takeda H., Zhu W. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3 and VEGF through disruption of HER/MET crosstalk. Cancer Res. 2015, 75:159-170.
50. Huston J.S., Levinson D., Mudgett-Hunter M., Tai M.S., Novotny J., Margolies M.N., Ridge R.J., Bruccoleri R.E., Haber E., Crea R., et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:5879-5883.
51. Igawa T., Tsunoda H., Kikuchi Y., Yoshida M., Tanaka M., Koga A., Sekimori Y., Orita T., Aso Y., Hattori K., Tsuchiya M. VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody. Protein Eng. Des. Sel. 2010, 23:667-677.
52. Jackman J., Chen Y., Huang A., Moffat B., Scheer J.M., Leong S.R., Lee W.P., Zhang J., Sharma N., Lu Y., Iyer S., Shields R.L., Chiang N., Bauer M.C., Wadley D., Roose-Girma M., Vandlen R., Yansura D.G., Wu Y., Wu L.C. Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J. Biol. Chem. 2010, 285:20850-20859.
53. Jakob C.G., Edalji R., Judge R.A., DiGiammarino E., Li Y., Gu J., Ghayur T. Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig) molecule. mAbs 2013, 5:358-363.
54. Johnson S., Burke S., Huang L., Gorlatov S., Li H., Wang W., Zhang W., Tuaillon N., Rainey J., Barat B., Yang Y., Jin L., Ciccarone V., Moore P.A., Koenig S., Bonvini E. Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion. J. Mol. Biol. 2010, 399:436-449.
55. Jost C., Plückthun A. Engineered proteins with desired specificity: DARPins, other alternative scaffolds and bispecific IgGs. Curr. Opin. Struct. Biol. 2014, 27:102-112.
56. Kelley B. Industralization of mAb production technology. The bioprocess industry at a crossroads. mAbs 2009, 1:443-452.
57. Kipriyanov S.M., Moldenhauer G., Schuhmacher J., Cochlovius B., Von der Lieth C.W., Matys E.R., Little M. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J. Mol. Biol. 1999, 293:41-56.
58. Kitazawa T., Igawa T., Sampei Z., Muto A., Kojima T., Soeda T., Yoshihashi K., Okuyama-Nishida Y., Saito H., Tsunoda H., Suzuki T., Adachi H., Miyazaki T., Ishii S., Kamata-Sakurai M., Iida T., Harada A., Esaki K., Funaki M., Moriyama C., Tanaka E., Kikuchi Y., Wakabayashi T., Wada M., Goto M., Toyoda T., Ueyama A., Suzuki S., Haraya K., Tachibana T., Kawabe Y., Shima M., Yoshioka A., Hattori K. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat. Med. 2012, 18:1570-1574.
59. Koefoed K., Steinaa L., Soderberg J.N., Kjaer I., Jacobsen H.J., Meijer P.J., Haurum J.S., Jensen A., Kragh M., Andersen P.S., Pedersen M.W. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. mAbs 2011, 3:584-595.
60. Kontermann R. Dual targeting strategies with bispecific antibodies. mAbs 2012, 4:185-197.
61. Kontermann R.E. Strategies for extended serum half-life of protein therapeutics. Curr. Opin. Biotechnol. 2011, 22:868-876.
62. Kreutz F.T., Xu D.Z., Suresh M.R. A new method to generate quadromas by electrofusion and FACS sorting. Hybridoma 1998, 17:267-273.
63. Labrijn A.F., Buijsse A.O., van den Bremer E.T., Verwilligen A.Y., Bleeker W.K., Thorpe S.J., Killestein J., Polman C.H., Aalberse R.C., Schuurman J., van de Winkel J.G., Parren P.W. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat. Biotechnol. 2009, 27:767-771.
64. Labrijn A.F., Meesters J.I., de Goeij B.E., van den Bremer E.T., Neijssen J., van Kampen M.D., Strumane K., Verploegen S., Kundu A., Gramer M.J., van Berkel P.H., van de Winkel J.G., Schuurman J., Parren P.W. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:5145-5150.
65. LaFleur D.W., Abramyan D., Kanakaraj P., Smith R.G., Shah R.R., Wang G., Yao X.T., Kankanala S., Boyd E., Zaritskaya L., Nam V., Puffer B.A., Buasen P., Kaithamana S., Burnette A.F., Krishnamurthy R., Patel D., Roschke V.V., Kiener P.A., Hilbert D.M., Barbas C.F. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides. mAbs 2013, 5:208-218.
66. Larbouret C., Robert B., Linard C., Teulon I., Gourgou S., Bibeau F., Martineau P., Santoro L., Pouget J.P., Pelegrin A., Azria D. Radiocurability by targeting tumor necrosis factor-alpha using a bispecific antibody in carcinoembryonic antigen transgenic mice. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69:1231-1237.
67. Lewis S.M., Wu X., Pustilnik A., Sereno A., Huang F., Rick H.L., Guntas G., Leaver-Fay A., Smith E.M., Ho C., Hansen-Estruch C., Chamberlain A.K., Truhlar S.M., Conner E.M., Atwell S., Kuhlman B., Demarest S.J. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat. Biotechnol. 2014, 32:191-198.
68. Liu Z., Leng E.C., Gunasekaran K., Pentony M., Shen M., Howard M., Stoops J., Manchulenko K., Razinkov V., Liu H., Fanslow W., Hu Z., Sun N., Hasegawa H., Clark R., Foltz I.N., Yan W. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J. Biol. Chem. 2015, (in the press).
69. Lu D., Jimenez X., Zhang H., Wu Y., Bohlen P., Witte L., Zhu Z. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res. 2001, 61:7002-7008.
70. Lu D., Zhang H., Koo H., Tonra J., Balderes P., Prewett M., Corcoran E., Mangalampalli V., Bassi R., Anselma D., Patel D., Kang X., Ludwig D.L., Hicklin D.J., Bohlen P., Witte L., Zhu Z. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J. Biol. Chem. 2005, 280:19665-19672.
71. Lu D., Zhang H., Ludwig D., Persaud A., Jimenez X., Burtrum D., Balderes P., Liu M., Bohlen P., Witte L., Zhu Z. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J. Biol. Chem. 2004, 279:2856-2865.
72. Mabry R., Lewis K.E., Moore M., McKernan P.A., Bukowski T.R., Bontadelli K., Brender T., Okada S., Lum K., West J., Kuijper J.L., Ardourel D., Franke S., Lockwood L., Vu T., Frank A., Appleby M.W., Wolf A., Reardon B., Hamacher N.B., Stevens B., Lewis P., Lewis K.B., Gilbertson D.G., Lantry M., Julien S.H., Ostrander C., Chan C., Byrnes-Blake K., Brody J., Presnell S., Meengs B., Levin S.D., Snavely M. Engineering of stable bispecific antibodies targeting IL-17A and IL-23. Protein Eng. Des. Sel. 2009, 23:115-127.
73. Mack M., Riethmüller G., Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:7021-7025.
74. Marvin J.S., Zhu Z. Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol. Sin. 2005, 26:649-658.
75. McWhirter, J., Macdonald, L.E., Stevens, S., Davis, S., Murphy, A.J., 2011. Common light chain mouse. WO/2011/097603. Regeneron Pharmaceuticals, Inc.
76. Merchant A.M., Zhu Z., Yuan J.Q., Goddard A., Adams C.W., Presta L.G., Carter P. An efficient route to human bispecific IgG. Nat. Biotechnol. 1998, 16:677-681.
77. Merchant M., Ma X., Maun H.R., Zheng Z., Peng J., Romero M., Huang A., Yang N.Y., Nishimura M., Greve J., Santell L., Zhang Y.W., Su Y., Kaufman D.W., Billeci K.L., Mai E., Moffat B., Lim A., Duenas E.T., Phillips H.S., Xiang H., Young J.C., Vande Woude G.F., Dennis M.S., Reilly D.E., Schwall R.H., Starovasnik M.A., Lazarus R.A., Yansura D.G. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E2987-E2996.
78. Metz S., Haas A.K., Daub K., Croasdale R., Stracke J., Lau W., Georges G., Josel H.P., Dziadek S., Hopfner K.P., Lammens A., Scheuer W., Hoffmann E., Mundigl O., Brinkmann U. Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:8194-8199.
79. Mimoto F., Igawa T., Kuramochi T., Katada H., Kadono S., Kamikawa T., Shida-Kawazoe M., Hattori K. Novel asymmetrically engineered antibody Fc variant with superior FcgammaR binding affinity and specificity compared with afucosylated Fc variant. mAbs 2013, 5:229-236.
80. Moore G.L., Bautista C., Pong E., Nguyen D.H., Jacinto J., Eivazi A., Muchhal U.S., Karki S., Chu S.Y., Lazar G.A. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. mAbs 2011, 3:546-557.
81. Müller D., Karle A., Meissburger B., Hofig I., Stork R., Kontermann R.E. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J. Biol. Chem. 2007, 282:12650-12660.
82. Nagorsen D., Kufer P., Baeuerle P.A., Bargou R. Blinatumomab: a historical perspective. Pharmacol. Ther. 2012, 136:334-342.
83. Nayak S.U., Griffiss J.M., McKenzie R., Fuchs E.J., Jurao R.A., An A.T., Ahene A., Tomic M., Hendrix C.W., Zenilman J.M. Safety and pharmacokinetics of XOMA 3AB, a novel mixture of three monoclonal antibodies against botulinum toxin A. Antimicrob. Agents Chemother. 2014, 58:5047-5053.
84. Niewoehner J., Bohrmann B., Collin L., Urich E., Sade H., Maier P., Rueger P., Stracke J.O., Lau W., Tissot A.C., Loetscher H., Ghosh A., Freskgard P.O. Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 2014, 81:49-60.
85. Nisonoff A., Rivers M.M. Recombination of a mixture of univalent antibody fragments of different specificity. Arch. Biochem. Biophys. 1961, 93:460-462.
86. Nowakowski A., Wang C., Powers D.B., Amersdorfer P., Smith T.J., Montgomery V.A., Sheridan R., Blake R., Smith L.A., Marks J.D. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:11346-11350.
87. Oates J., Jakobsen B.K. ImmTACs: Novel bi-specific agents for targeted cancer therapy. Oncoimmunol 2013, 2:e22891.
88. Orcutt K.D., Ackerman M.E., Cieslewicz M., Quiroz E., Slusarczyk A.L., Frangioni J.V., Wittrup K.D. A modular IgG-scFv bispecific antibody topology. Protein Eng. Des. Sel. 2009, 23:221-228.
89. Ott M.G., Marme F., Moldenhauer G., Lindhofer H., Hennig M., Spannagl R., Essing M.M., Linke R., Seimetz D. Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int. J. Cancer 2012, 130:2195-2203.
90. Perchiacca J.M., Tessier P.M. Engineering aggregation-resistant antibodies. Annu. Rev. Chem. Biomol. Eng. 2012, 3:263-286.
91. Qiu X., Audet J., Wong G., Fernando L., Bello A., Pillet S., Alimonti J.B., Kobinger G.P. Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Sci. Rep. 2013, 3:3365.
92. Renner C., Hartmann F., Pfreundschuh M. Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Cancer Immunol. Immunother. 1997, 45:184-186.
93. Ridgway J.B., Presta L.G., Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 1996, 9:617-621.
94. Riethmüller G. Symmetry breaking: bispecific antibodies, the beginnings, and 50 years on. Cancer Immun. 2012, 12:12.
95. Roopenian D.C., Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 2007, 7:715-725.
96. Rossi E.A., Goldenberg D.M., Cardillo T.M., McBride W.J., Sharkey R.M., Chang C.H. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:6841-6846.
97. Rossi E.A., Goldenberg D.M., Cardillo T.M., Stein R., Chang C.H. Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood 2009, 113:6161-6171.
98. Rossi E.A., Rossi D.L., Stein R., Goldenberg D.M., Chang C.H. A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. Cancer Res. 2010, 70:7600-7609.
99. Sampei Z., Igawa T., Soeda T., Okuyama-Nishida Y., Moriyama C., Wakabayashi T., Tanaka E., Muto A., Kojima T., Kitazawa T., Yoshihashi K., Harada A., Funaki M., Haraya K., Tachibana T., Suzuki S., Esaki K., Nabuchi Y., Hattori K. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS ONE 2013, 8:e57479.
100. Saphire E.O., Parren P.W., Pantophlet R., Zwick M.B., Morris G.M., Rudd P.M., Dwek R.A., Stanfield R.L., Burton D.R., Wilson I.A. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design. Science 2001, 293:1155-1159.
101. Schaefer G., Haber L., Crocker L.M., Shia S., Shao L., Dowbenko D., Totpal K., Wong A., Lee C.V., Stawicki S., Clark R., Fields C., Lewis Phillips G.D., Prell R.A., Danilenko D.M., Franke Y., Stephan J.P., Hwang J., Wu Y., Bostrom J., Sliwkowski M.X., Fuh G., Eigenbrot C. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011, 20:472-486.
102. Schaefer W., Regula J.T., Bahner M., Schanzer J., Croasdale R., Durr H., Gassner C., Georges G., Kettenberger H., Imhof-Jung S., Schwaiger M., Stubenrauch K.G., Sustmann C., Thomas M., Scheuer W., Klein C. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:11187-11192.
103. Schanzer J.M., Wartha K., Croasdale R., Moser S., Kunkele K.P., Ries C., Scheuer W., Duerr H., Pompiati S., Pollman J., Stracke J., Lau W., Ries S., Brinkmann U., Klein C., Umana P. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties. J. Biol. Chem 2014, 289:18693-18706.
104. Shalaby M.R., Shepard H.M., Presta L., Rodrigues M.L., Beverley P.C., Feldmann M., Carter P. Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene. J. Exp. Med. 1992, 175:217-225.
105. Sharkey R.M., Cardillo T.M., Rossi E.A., Chang C.H., Karacay H., McBride W.J., Hansen H.J., Horak I.D., Goldenberg D.M. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat. Med. 2005, 11:1250-1255.
106. Sharkey R.M., Rossi E.A., McBride W.J., Chang C.H., Goldenberg D.M. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin. Nucl. Med. 2010, 40:190-203.
107. Spiess C., Bevers J., 3rd, Jackman J., Chiang N., Nakamura G., Dillon M., Liu H., Molina P., Elliott J.M., Shatz W., Scheer J.M., Giese G., Persson J., Zhang Y., Dennis M.S., Giulianotti J., Gupta P., Reilly D., Palma E., Wang J., Stefanich E., Scheerens H., Fuh G., Wu L.C. Development of a human IgG4 bispecific antibody for dual targeting of interleukin-4 (IL-4) and interleukin-13 (IL-13) cytokines. J. Biol. Chem. 2013, 288:26583-26593.
108. Spiess C., Merchant M., Huang A., Zheng Z., Yang N.Y., Peng J., Ellerman D., Shatz W., Reilly D., Yansura D.G., Scheer J.M. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat. Biotechnol. 2013, 31:753-758.
109. Staerz U.D., Kanagawa O., Bevan M.J. Hybrid antibodies can target sites for attack by T cells. Nature 1985, 314:628-631.
110. Stork R., Müller D., Kontermann R.E. A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G. Protein Eng. Des. Sel. 2007, 20:569-576.
111. Strop P., Ho W.H., Boustany L.M., Abdiche Y.N., Lindquist K.C., Farias S.E., Rickert M., Appah C.T., Pascua E., Radcliffe T., Sutton J., Chaparro-Riggers J., Chen W., Casas M.G., Chin S.M., Wong O.K., Liu S.H., Vergara G., Shelton D., Rajpal A., Pons J. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J. Mol. Biol. 2012, 420:204-219.
112. Suresh M.R., Cuello A.C., Milstein C. Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:7989-7993.
113. Tan P.H., Sandmaier B.M., Stayton P.S. Contributions of a highly conserved VH/VL hydrogen bonding interaction to scFv folding stability and refolding efficiency. Biophys. J. 1998, 75:1473-1482.
114. Tijink B.M., Laeremans T., Budde M., Stigter-van Walsum M., Dreier T., de Haard H.J., Leemans C.R., van Dongen G.A. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol. Cancer. Ther. 2008, 7:2288-2297.
115. van den Beucken T., van Neer N., Sablon E., Desmet J., Celis L., Hoogenboom H.R., Hufton S.E. Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains. J. Mol. Biol. 2001, 310:591-601.
116. van der Neut Kolfschoten M., Schuurman J., Losen M., Bleeker W.K., Martinez-Martinez P., Vermeulen E., den Bleker T.H., Wiegman L., Vink T., Aarden L.A., De Baets M.H., van de Winkel J.G., Aalberse R.C., Parren P.W. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007, 317:1554-1557.
117. Von Kreudenstein T.S., Escobar E., Lario P.I., D'Angelo I., Brault K., Kelly J., Durocher Y., Baardsnes J., Woods J.R., Xie M.H., Girod P.A., Suits M., Boulanger M.J., Poon D., Ng G.Y., Dixit S.B. Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. mAbs 2013, 5:646-654.
118. Walsh G. Biopharmaceutical benchmarks 2014. Nat. Biotechnol. 2014, 32:992-1000.
119. Ward E.S., Gussow D., Griffiths A.D., Jones P.T., Winter G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989, 341:544-546.
120. Watts R.J., Dennis M.S. Bispecific antibodies for delivery into the brain. Curr. Opin. Chem. Biol. 2013, 17:393-399.
121. Weinblatt M., Schiff M., Goldman A., Kremer J., Luggen M., Li T., Chen D., Becker J.C. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis. 2007, 66:228-234.
122. Weiner L.M., Clark J.I., Davey M., Li W.S., Garcia de Palazzo I., Ring D.B., Alpaugh R.K. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Cancer Res. 1995, 55:4586-4593.
123. Wranik B.J., Christensen E.L., Schaefer G., Jackman J.K., Vendel A.C., Eaton D. LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies. J. Biol. Chem. 2012, 287:43331-43339.
124. Wu C., Ying H., Bose S., Miller R., Medina L., Santora L., Ghayur T. Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. mAbs 2009, 1:339-347.
125. Wu C., Ying H., Grinnell C., Bryant S., Miller R., Clabbers A., Bose S., McCarthy D., Zhu R.R., Santora L., Davis-Taber R., Kunes Y., Fung E., Schwartz A., Sakorafas P., Gu J., Tarcsa E., Murtaza A., Ghayur T. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat. Biotechnol. 2007, 25:1290-1297.
126. Yu Y.J., Zhang Y., Kenrick M., Hoyte K., Luk W., Lu Y., Atwal J., Elliott J.M., Prabhu S., Watts R.J., Dennis M.S. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med. 2011, 3:84ra44.
127. Zhu Z., Presta L.G., Zapata G., Carter P. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci. 1997, 6:781-788.